4.6 Article

Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by RENAL nephrometry score

期刊

BJU INTERNATIONAL
卷 114, 期 5, 页码 708-718

出版社

WILEY-BLACKWELL
DOI: 10.1111/bju.12580

关键词

carcinoma; renal cell; disease-free survival; Stage 2; R; E; N; A; L; nephrometry; progression-free survival; nephrectomy

向作者/读者索取更多资源

ObjectiveWe evaluated survival outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for clinical T2 renal masses (cT2RM) controlling for R.E.N.A.L. nephrometry score. Patients and MethodsA two-centre study comprised of 202 patients with cT2RM who underwent RN (122) or PN (80) between July 2002 and June 2012 (median follow-up 41.5 months). Kaplan-Meier analysis compared overall survival (OS), cancer-specific survival (CSS) and progression-free survival (PFS) among the entire cohort and within categories of R.E.N.A.L. nephrometry score of 10 and <10. Association between procedure and PFS and OS was analysed using Cox-proportional hazard. ResultsThere were no significant differences between PN and RN in clinical T stage and R.E.N.A.L. nephrometry scores. For RN and PN, the 5-year PFS was 69.8% and 79.9% (P = 0.115), CSS was 82.5% and 86.7% (P = 0.407), and OS was 80% and 83.3% (P = 0.291). Cox regression showed no association between RN vs PN and PFS; a R.E.N.A.L. nephrometry score of 10 was associated with a shorter PFS (hazard ratio 6.69, P = 0.002). Kaplan-Meier analysis for RN vs PN showed no difference in PFS for entire cohort or within the R.E.N.A.L. nephrometry score categories of 10 and <10. The PFS was better for those with R.E.N.A.L nephrometry scores of <10 vs 10 (P < 0.001) and for cT2a vs cT2b tumours (P = 0.012). OS was no different between cT2a and cT2b tumours; patients with R.E.N.A.L. nephrometry scores of 10 were more likely to die from disease (P < 0.001) or any cause (P < 0.001) vs those with R.E.N.A.L. nephrometry scores of <10. ConclusionsPN may be oncologically effective for cT2RM. A R.E.N.A.L nephrometry score of 10 is negatively associated with OS among cT2RM compared with a score of <10 and provides additional risk assessment beyond clinical T stage. Further follow-up and prospective randomised investigation is requisite to confirm efficacy of PN for cT2RM.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据